Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 348 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Temozolomide (temodar) Clear all
Completed Phase 2 Interventional Results available

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

NCT01143402
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IV Uveal Melanoma
Interventions
Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Selumetinib, Temozolomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
32
States / cities
Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Medical Treatment of "High-Risk" Neurofibromas

NCT00846430
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin)
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
2 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

NCT02116777
View directory record Official record
Conditions
Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Malignant Solid Neoplasm, Refractory Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, Temozolomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 1 Interventional

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

NCT00629187
View directory record Official record
Conditions
Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions
Temozolomide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

NCT05432804
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

NCT01217437
View directory record Official record
Conditions
Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Medulloblastoma, Refractory Peripheral Primitive Neuroectodermal Tumor
Interventions
Bevacizumab, Irinotecan Hydrochloride, Temozolomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 3 Interventional

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

NCT03149575
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
Interventions
VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin
Drug
Lead sponsor
DelMar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide Chronotherapy for High Grade Glioma

NCT02781792
View directory record Official record
Conditions
Glioma, Glioblastoma Multiforme
Interventions
Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Sep 30, 2026, 2:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02455557
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Other · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

NCT00389090
View directory record Official record
Conditions
Glioma, Astrocytoma, Oligodendroglioma, Oligoastrocytoma
Interventions
Temozolomide and O6-Benzylguanine
Drug
Lead sponsor
Keryx / AOI Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Active, not recruiting Phase 1 Interventional

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

NCT04337177
View directory record Official record
Conditions
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Interventions
VAL-413, Temozolomide
Drug
Lead sponsor
Valent Technologies, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Beyond Progression (BBP)

NCT01740258
View directory record Official record
Conditions
Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions
Radiation Therapy, Temozolomide, Bevacizumab
Radiation · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

NCT00761280
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma
Interventions
trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine
Drug · Device · Procedure
Lead sponsor
Isarna Therapeutics GmbH
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Edison, New Jersey • Mineola, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

NCT00650923
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Interventions
ziv-aflibercept, radiation therapy, temozolomide, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Metformin in Children With Relapsed or Refractory Solid Tumors

NCT01528046
View directory record Official record
Conditions
Solid Tumors, Primary Brain Tumors
Interventions
Vincristine, Irinotecan, Temozolomide, Metformin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Hartford, Connecticut • Wilmington, Delaware • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

NCT01124734
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Interleukin-2, Temozolomide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

NCT00039494
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
139
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated No phase listed Observational Results available

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

NCT01452854
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Results available

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

NCT00629343
View directory record Official record
Conditions
Soft Tissue Sarcoma, Mesothelioma
Interventions
Azacitidine, Temozolomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Not yet recruiting Phase 3 Interventional

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

NCT06448286
View directory record Official record
Conditions
Glioblastoma
Interventions
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging, Radiation Therapy, Surgical Procedure, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

NCT01236560
View directory record Official record
Conditions
Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Spinal Cord Neoplasm
Interventions
Bevacizumab, Temozolomide, Vorinostat
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
124
States / cities
Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma

NCT00311584
View directory record Official record
Conditions
Neuroblastoma
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT06709495
View directory record Official record
Conditions
Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim
Drug · Biological
Lead sponsor
David S Shulman, MD
Other
Eligibility
12 Years to 49 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 30, 2026, 2:32 AM EDT